Heska Co. (NASDAQ:HSKA – Get Rating) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 545,100 shares, an increase of 15.8% from the January 31st total of 470,800 shares. Based on an average daily volume of 114,300 shares, the short-interest ratio is presently 4.8 days. Currently, 5.5% of the shares of the company are sold short.
Insider Transactions at Heska
In other Heska news, CEO Kevin S. Wilson acquired 11,018 shares of Heska stock in a transaction that occurred on Friday, January 6th. The stock was acquired at an average cost of $58.62 per share, for a total transaction of $645,875.16. Following the purchase, the chief executive officer now owns 167,072 shares of the company’s stock, valued at $9,793,760.64. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Kevin S. Wilson acquired 11,018 shares of the company’s stock in a transaction dated Friday, January 6th. The stock was bought at an average cost of $58.62 per share, with a total value of $645,875.16. Following the acquisition, the chief executive officer now owns 167,072 shares of the company’s stock, valued at approximately $9,793,760.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin S. Wilson purchased 3,440 shares of the company’s stock in a transaction on Thursday, December 22nd. The shares were purchased at an average cost of $59.64 per share, with a total value of $205,161.60. Following the purchase, the chief executive officer now owns 156,054 shares of the company’s stock, valued at $9,307,060.56. The disclosure for this purchase can be found here. 11.00% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Captrust Financial Advisors increased its holdings in Heska by 15.9% in the 4th quarter. Captrust Financial Advisors now owns 13,834 shares of the medical research company’s stock worth $860,000 after buying an additional 1,897 shares during the period. State of Wisconsin Investment Board lifted its holdings in Heska by 15.0% in the fourth quarter. State of Wisconsin Investment Board now owns 12,082 shares of the medical research company’s stock valued at $751,000 after acquiring an additional 1,573 shares during the period. Legal & General Group Plc boosted its position in Heska by 2.2% in the 4th quarter. Legal & General Group Plc now owns 24,640 shares of the medical research company’s stock worth $1,532,000 after purchasing an additional 535 shares in the last quarter. Millennium Management LLC grew its stake in shares of Heska by 82.7% during the 4th quarter. Millennium Management LLC now owns 153,941 shares of the medical research company’s stock worth $9,569,000 after purchasing an additional 69,688 shares during the period. Finally, Morgan Stanley lifted its stake in shares of Heska by 18.6% in the 4th quarter. Morgan Stanley now owns 199,050 shares of the medical research company’s stock valued at $12,373,000 after purchasing an additional 31,249 shares during the period. 99.01% of the stock is currently owned by hedge funds and other institutional investors.
Heska Stock Up 1.1 %
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on HSKA. Piper Sandler decreased their price target on Heska from $165.00 to $150.00 in a research note on Thursday. Morgan Stanley downgraded shares of Heska from an “equal weight” rating to an “underweight” rating and set a $58.00 target price for the company. in a report on Friday, January 6th. Finally, Alliance Global Partners boosted their target price on shares of Heska from $119.00 to $129.00 in a report on Wednesday, March 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $121.75.
About Heska
Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland.
Featured Stories
- Get a free copy of the StockNews.com research report on Heska (HSKA)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.
